https://orcid.org/0000-0002-7510-9428
References
- Maredia H, Kwatra SG. Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis. J Dermatol Treat. 2020;1–4.
- Whang KA, Kang S, Kwatra SG. Inpatient burden of prurigo nodularis in the United States. Medicines. 2019;6(3):88.
- Zeidler C, Ständer S. The pathogenesis of Prurigo nodularis – ‘Super-Itch’ in exploration. Eur J Pain. 2016;20(1):37–40.
- Heath MS, Seger EW, Feldman SR. Atopic dermatitis: a look into systemic treatments and adherence considerations. J Dermatol Treat. 2018;29(6):535–535.
- Kolli S, Haidari W, Feldman S. Treatment-resistant prurigo nodularis. Clin Cosmet Invest Dermatol. 2019;12:345–346.
- Pölking J, Zeidler C, Schedel F, et al. Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(10):1754–1760.
- Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutaneous Pathol. 2010;37(5):578–586.